Linked CIViC Profile: PIK3CA MUTATION
Evidence Level Distribution
Level A: 1Level B: 24Level C: 1Level D: 14
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Breast Cancer | Alpelisib,Fulvestrant | 5 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Anti-EGFR Monoclonal Antibody | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Everolimus | 4 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Alpelisib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor | 4 |
| B | Predictive | Supports | Sensitivity/Response | Cancer | Capivasertib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Cabozantinib | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Endometrial Cancer | Ridaforolimus,Temsirolimus | 3 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Cancer | Dactolisib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Radiation Therapy,Taselisib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Stomach Cancer | Capivasertib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Capivasertib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor | 3 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Everolimus,MTOR Kinase Inhibitor PP242 | 3 |
| D | Predictive | Supports | Sensitivity/Response | Endometrial Cancer | Pictilisib | 3 |
| B | Prognostic | Supports | Better Outcome | Breast Cancer | 3 | |
| B | Predictive | Supports | Resistance | Breast Cancer | Trastuzumab | 3 |
| B | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 3 |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | 3 |